Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 10/20 | 0.62 |
| ▸ | ELANE | P08246 | 2/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930225 | 1.00 | CCR3 (0.62) | CCR3ELANETACR3KDRKDM4E | |
| SCHEMBL3930227 | 1.00 | CCR3 (0.62) | CCR3ELANETACR3KDRKDM4E | |
| SCHEMBL3935460 | 0.92 | CCR3 (0.67) | CCR3ELANEALDH1A1 | |
| SCHEMBL3935453 | 0.92 | CCR3 (0.67) | CCR3ELANEALDH1A1 | |
| SCHEMBL3929562 | 0.91 | CCR3 (0.59) | CCR3ELANE | |
| SCHEMBL3929560 | 0.91 | CCR3 (0.59) | CCR3ELANE | |
| SCHEMBL3926453 | 0.89 | CCR3 (0.59) | CCR3 | |
| SCHEMBL3926458 | 0.89 | CCR3 (0.59) | CCR3 | |
| SCHEMBL8014171 | 0.88 | CCR3 (0.66) | CCR3ELANE | |
| SCHEMBL7608481 | 0.88 | CCR3 (0.66) | CCR3ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026848-A1 | IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-01-23 | — | — | US | claimed |
| US-20240390411-A1 | COMPOSITION COMPRISING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | SEIKAGAKU CORPORATION (JP) | 2024-11-28 | — | — | US | claimed |
| US-20240277684-A1 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | UNIVERSITY OF SOUTH FLORIDA | 2024-08-22 | — | — | US | claimed |
| US-20230270732-A1 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | NATIONAL INSTITUTES OF HEALTH | 2023-08-31 | — | — | US | claimed |
| WO-2023023269-A1 | IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-02-23 | — | — | WO | claimed |
| EP-3689386-B1 | NON-CELLULAR ROOT CANAL FILLER AND NON-CELLULAR DENTAL TISSUE REGENERATION PROMOTING KIT | KOWA CO (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-3949991-B1 | ACELLULAR ROOT CANAL FILLER AND ACELLULAR DENTAL TISSUE REGENERATION PROMOTING KIT | KOWA CO (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | disclosed |
| US-20250026848-A1 | IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-01-23 | — | — | US | disclosed |
| US-12186413-B2 | Non-cellular root canal filler and non-cellular dental tissue regeneration promotion kit | KOWA COMPANY, LTD. (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20240425576-A1 | METHOD FOR TREATING A PERIOHERAL ARTERIAL DISEASE | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2024-12-26 | — | — | US | disclosed |
| US-20240390411-A1 | COMPOSITION COMPRISING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | SEIKAGAKU CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2023023269-A1 | IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-115697334-A | Methods of improving retinal related disease outcomes using CCR3 inhibitors | 万能溶剂有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220401528-A1 | DENTAL PRETREATMENT MATERIAL AND DENTAL TISSUE REGENERATION KIT | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2022-12-22 | — | — | US | disclosed |
| US-20220362109-A1 | NON-CELLULAR ROOT CANAL FILLER AND NON-CELLULAR DENTAL TISSUE REGENERATION PROMOTING KIT | KOWA COMPANY, LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220213487-A1 | CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | disclosed |
| US-20220133776-A1 | COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | SEIKAGAKU CORPORATION (JP) | 2022-05-05 | — | — | US | disclosed |
| EP-3949991-A1 | ACELLULAR ROOT CANAL FILLER AND ACELLULAR DENTAL TISSUE REGENERATION PROMOTING KIT | Kowa Company, Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12186413-B2 | Non-cellular root canal filler and non-cellular dental tissue regeneration promotion kit | MMP1, CTRL, KIT | CCR3 2569/4885ELANE 1548/4885TACR3 3839/4885 |
| US-20240277684-A1 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | CCR2, CCR1, CCL2 | CCR3 6/4885ELANE 583/4885TACR3 393/4885 |
| US-20220362109-A1 | NON-CELLULAR ROOT CANAL FILLER AND NON-CELLULAR DENTAL TISSUE REGENERATION PROMOTING KIT | KIT, CTRL, MMP1 | CCR3 2155/4885ELANE 1559/4885TACR3 3718/4885 |
| US-20240390411-A1 | COMPOSITION COMPRISING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | CCL5, CCL2, CCR5 | CCR3 13/4885ELANE 135/4885TACR3 638/4885 |
| US-20220401528-A1 | DENTAL PRETREATMENT MATERIAL AND DENTAL TISSUE REGENERATION KIT | CCL11, MMP11, PRSS3 | CCR3 4/4885ELANE 278/4885TACR3 2415/4885 |
| US-20220133776-A1 | COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | CCL5, CCL2, ACKR3 | CCR3 16/4885ELANE 229/4885TACR3 947/4885 |
| US-20230270732-A1 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | CCR2, CCR1, CCL2 | CCR3 6/4885ELANE 583/4885TACR3 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.